End-of-life criteria [If you consider that the technology meets the end-of-life criteria in the addendum to the guide to the methods of technology appraisal, please complete the table below. Delete this section if not applicable.] Table 8 End-of-life criteria B.2.13 (page [X]) – Criterion Data available The treatment is indicated for patients with a [State mean and/or median life expectancy, and source of the data] short life expectancy, normally less than 24 months There is sufficient evidence to indicate that [State mean and/or median extension to life, and source of the data] the treatment offers an extension to life, normally of at least an additional 3 months, compared with current NHS treatment Budget impact [Provide summary values of the budget impact in the table below. Provide cross references to the assumptions and methods used in calculating the values] Table 9 Budget impact [Document] (page [X]) – Company estimate Cross reference
End-of-life criteria [If you consider that the technology meets the end-of-life criteria in the addendum to the guide to the methods of technology appraisal, please complete the table below. Delete this section if not applicable.] Table 8 End-of-life criteria – B.2.13 (page [X]) Criterion Data available The treatment is indicated for patients with a short life expectancy, normally less than 24 months [State mean and/or median life expectancy, and source of the data] There is sufficient evidence to indicate that the treatment offers an extension to life, normally of at least an additional 3 months, compared with current NHS treatment [State mean and/or median extension to life, and source of the data] Budget impact [Provide summary values of the budget impact in the table below. Provide cross references to the assumptions and methods used in calculating the values] Table 9 Budget impact – [Document] (page [X]) Company estimate Cross reference
company-evidence-submission-summary-template-for-committee-apr-17.docx